ChromaDex (CDXC) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to ChromaDex (CDXC) Misses Q2 EPS by 2c

ChromaDex Corporation Reports Second Quarter 2018 Financial Results   

August 9, 2018 4:01 PM EDT

IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today second quarter 2018 financial results.

Second Quarter 2018 Highlights vs. Second Quarter 2017

Net sales up 85%, fueled by growth of TRU NIAGEN®;TRU NIAGEN sales at 66% of NIAGEN-related sales, up from 7%;NIAGEN®-related sales at 73% of total sales, up from 50%;Gross profit as a percentage of net sales... More